Treace Medical Concepts (NASDAQ:TMCI) Stock Crosses Above 50-Day Moving Average – Time to Sell?

Posted by Stanley Muller on Oct 27th, 2026

Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $4.41 and traded as high as $4.43. Treace Medical Concepts shares last traded at $4.42, with a volume of 157,213 shares trading hands.

Analyst Upgrades and Downgrades

TMCI has been the topic of a number of recent analyst reports. Truist Financial raised their target price on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the stock a “hold” rating in a research note on Monday, August 10th. Weiss Ratings upgraded shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Treace Medical Concepts presently has a consensus rating of “Reduce” and a consensus target price of $5.17.

Check Out Our Latest Analysis on TMCI

Treace Medical Concepts Stock Up 3.5%

The firm has a market capitalization of $287.48 million, a PE ratio of -4.75 and a beta of 1.48. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.90 and a quick ratio of 1.95. The company has a 50-day moving average price of $4.41 and a 200 day moving average price of $3.21.

Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06. The firm had revenue of $45.38 million during the quarter, compared to analysts’ expectations of $44.02 million. Treace Medical Concepts had a negative return on equity of 71.37% and a negative net margin of 28.99%. Analysts forecast that Treace Medical Concepts, Inc. will post -0.83 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO John Treace acquired 39,944 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was acquired at an average cost of $4.44 per share, with a total value of $177,351.36. Following the acquisition, the chief executive officer directly owned 7,388,383 shares in the company, valued at $32,804,420.52. This represents a 0.54% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders purchased 55,944 shares of company stock valued at $246,841. Corporate insiders own 23.42% of the company’s stock.

Hedge Funds Weigh In On Treace Medical Concepts

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE bought a new stake in Treace Medical Concepts in the 2nd quarter valued at $13,154,000. BlackRock Inc. purchased a new stake in Treace Medical Concepts in the 2nd quarter worth $5,492,000. Weber Capital Management LLC ADV bought a new position in shares of Treace Medical Concepts during the 2nd quarter valued at about $2,346,676. Renaissance Technologies LLC bought a new position in shares of Treace Medical Concepts during the 1st quarter valued at about $701,000. Finally, Ieq Capital LLC bought a new position in shares of Treace Medical Concepts during the 2nd quarter valued at about $437,000. Institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Company Profile

(Get Free Report)

Treace Medical Concepts, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of bunion deformities and other conditions affecting the foot and ankle. The company’s technologies are designed to address the underlying structural causes of bunions and support more stable correction than traditional surgical approaches.

Treace’s primary product is the Lapiplasty 3D Bunion Correction System, which is used by foot and ankle surgeons to correct bunions in three dimensions.